LITAF binding site peptides and methods of using the same

Details LITAF binding site peptides and methods of using the same LITAF binding site peptides and methods of using the same

2008-04-22

2008-04-22

Guzo, David (Department: 1636)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S358000

Reexamination Certificate

active

07361735

ABSTRACT:
The invention provides molecules containing nucleic acid sequences for fragments of LPS-induced TNF-α factor (LITAF) and vectors containing these sequences. Also provided are molecules that contain the peptide sequence SQTWREPGAAGSPFHL, or homologs thereof. Such molecules may be useful in the treatment of diseases that relate to the expression of TNF-α, where treatment involves the modulation of this expression. The invention also provides methods for identifying compounds that inhibit or enhance the transcription of TNF-α.

REFERENCES:
patent: 6077693 (2000-06-01), Tang et al.
patent: 6566501 (2003-05-01), Amar
patent: WO02086094 (2002-10-01), None
Myokai et al., “A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor α gene expression: Molecular cloning, sequencing, characterization, and chromosomal assignment,”Proc. Natl. Acad. Sci. USA, 96:4518-4523 (1999).
Neumann et al., “Gene transfer into mouse lyoma cells by electroporation in high electric fields,”EMBO J., 1(7):841-845 (1982).
Polyak et al., “A model for p53-induced apoptosis,”Nature, 389(6648):300-305 (1997).
Smith and Waterman, “Comparison of Biosequences,”Adv. Appl. Math. 2:482-489(1981).
Suganuma et al., “A New Process Of Cancer Prevention Mediated Through Inhibitor Of Tumor Necrosis Factor α Expression,”Cancer Res., 56(16):3711-3715 (1996).
Sugarman et al., “Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro,”Science, 230(4728):943-945 (1985).
Talmadge et al., “Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor,”Cancer Res., 48(3):544-550 (1988).
Tang et al., “Identification and functional characterization of a novel binding site on TNF-α promoter,”Proc. Natl. Acad. Sci. USA, 100(7):4096-4101 (2003).
Uglialoro et al., “Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter,”Tissue Antigens, 52(4):359-367 (1998).
Vousden and Lu, “Live or Let Die: The Cell's Response to p53,”Nat. Rev. Cancer, 2(8):594-604 (2002).
Xaus et al., “LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-α,”Blood, 95(12):3823-3831 (2000).
Adams and Cory, “The Bcl-2 Protein Family: Arbiters of Cell Survival,”Science, 281(5381):1322-1326 (1998).
Alexander et al., “Treatment with Recombinant Human Tumor Necrosis Factor-Alpha Protects Rats Against the Lethality, Hypotension, and Hypothermia of Gram-Negative Sepsis,”J. Clin. Invest., 88:34-39 (1991).
Amar and Han, “Regulation of tumour necrosis factor-α gene expression,”Appl. Genomics Proteomics1(1):31-44 (2002).
Beutler and Cerami, “The Biology of Cachectin/TNF—A Primary Mediator of the Host Response,”Ann. Rev. Immunol., 7:625-655 (1989).
Brugarolas et al., “Radiation-induced cell cycle arrest compromised by p21 deficiency,”Nature, 377(6549):552-557 (1995).
Capecchi, M.R., “High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells,”Cell, 22(2 Pt. 2):479-488 (1980).
Cepko et al., “Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector,”Cell, 37(3):1053-1062 (1984).
Donis-Keller, H., “Phy M: an RNase activity specific for U and A residues useful in RNA sequence analysis,”Nucleic Acids Res., 8(14):3133-3142 (1980).
Drouet et al., “Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-α promoter in primary macrophages,”J. Immunol., 147(5):1694-1700 (1991).
El-Delry et al., “WAF1, A Potential Mediator of p53 Tumor Suppression,”Cell, 75(4):817-825 (1993).
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Pro. Natl. Acad. Sci. USA, 84:7413-7417 (1987).
Galas and Schmitz, “DNAase footprinting: a simple method for the detection of protein-DNA binding specificity,”Nucleic Acids Res., 5(9):3157-3170 (1978).
Graham and van der Eb, “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virology, 52(2):456-467 (1973).
Horng et al., “TIRAP: an adapter molecule in the Toll signaling pathway,”Nat. Immunol., 2(9):835-841 (2001).
IUPAC Commission on the Nomenclature of Organic Chemistry and IUPAC-IUB Commission on Biochemical Nomenclature, “Nomenclature of α-Amino Acids (Recommendations, 1974),”Biochemistry14(2):449-462 (1975).
Kinzler and Vogelstein, “Life (and death) in a malignant tumour,”Nature, 379(6560):19-20 (1996).
Ko and Prives, “p53: puzzle and paradigm,”Genes&Dev., 10(9):1054-1072 (1996).
Ksontini et al., “Disparate Roles for TNF-α and Fas Ligand in Concanavalin A-Induced Hepatitis,”J. Immunol., 160:4082-4089 (1998).
Levine, A.J., “p53, the Cellular Gatekeeper for Growth and Division,”Cell, 88(3):323-331 (1997).
Li et al., “Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expression wild-type and mutant p53,”Proc. Natl. Acad. Sci. USA, 99(16):10364-10369 (2002).
McClane et al., “Functional Consequences of Adenovirus-Mediated Murine Pancreatic Gene Transfer,”Hum. Gene Ther., 8(6):739-746 (1997).
Miyashita and Reed, “Tumor Suppressor p53 Is a Direct Transcriptional Activator of the Human Bax Gene,”Cell, 80(2):293-299 (1995).
Morris et al., “A peptide carrier for the delivery of biologically active proteins into mammalian cells,”Nat. Biotechnol., 19(12):1173-1176 (2001).
Munshi et al., “Lipopolysaccharide-Induced Apoptosis of Endothelial Cells and Its Inhibition by Vascular Endothelial Growth Factor,”J. Immunol., 168(11):5860-5866 (2002).

Affiliated with

Also associated with

Rating

LITAF binding site peptides and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LITAF binding site peptides and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LITAF binding site peptides and methods of using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2777716